<DOC>
	<DOCNO>NCT00445705</DOCNO>
	<brief_summary>This study explore safety effectiveness different dos AGN 203818 treat pain associate fibromyalgia syndrome . The study conduct 2 part . Part A enrolled 211 pt dose either 3 , 20 , 60 mg BID AGN 203818 placebo 4 week treatment duration . Part B enroll 440 pt dose either 20 , 100 , 160 mg BID AGN 203818 placebo 12 week treatment duration .</brief_summary>
	<brief_title>Safety Efficacy AGN 203818 Pain Associated With Fibromyalgia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Diagnosis fibromyalgia syndrome Moderate severe pain associate fibromyalgia Any uncontrolled disease Pregnant nursing female</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>